{"id":50318,"date":"2026-01-12T09:34:03","date_gmt":"2026-01-12T08:34:03","guid":{"rendered":"https:\/\/ellipse.prbb.org\/?p=50318"},"modified":"2026-01-12T09:34:02","modified_gmt":"2026-01-12T08:34:02","slug":"violet-pharmaceuticals-una-nova-spin-off-que-utilitza-arnm-per-millorar-la-immunoterapia-contra-el-cancer","status":"publish","type":"post","link":"https:\/\/ellipse.prbb.org\/ca\/violet-pharmaceuticals-una-nova-spin-off-que-utilitza-arnm-per-millorar-la-immunoterapia-contra-el-cancer\/","title":{"rendered":"VIOLET Pharmaceuticals, una nova spin-off que utilitza ARNm per millorar la immunoter\u00e0pia contra el c\u00e0ncer"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong><a rel=\"noreferrer noopener\" href=\"https:\/\/www.linkedin.com\/company\/violet-pharmaceuticals\/\" target=\"_blank\">VIOLET Pharmaceuticals<\/a><\/strong>, una nova spin-off de l&#8217;<a rel=\"noreferrer noopener\" href=\"https:\/\/www.imim.es\/en_index.html\" target=\"_blank\">Hospital del Mar Research Institute<\/a>, s&#8217;ha creat amb l&#8217;objectiu de millorar l&#8217;efic\u00e0cia de les immunoter\u00e0pies per al c\u00e0ncer metast\u00e0tic.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">L&#8217;empresa aborda una important necessitat m\u00e8dica no satisfeta: <a href=\"https:\/\/ellipse.prbb.org\/ca\/toni-celia-terrassa-imim-mes-del-90-de-les-morts-per-cancer-son-degudes-a-una-metastasi\/\" target=\"_blank\" rel=\"noreferrer noopener\"><strong>els tumors metast\u00e0tics<\/strong><\/a> <strong>sovint eviten la detecci\u00f3 immunit\u00e0ria<\/strong> limitant la presentaci\u00f3 d&#8217;ant\u00edgens a la seva superf\u00edcie, cosa que fa que les <a href=\"https:\/\/ellipse.prbb.org\/ca\/tag\/immunoterapia\/\" target=\"_blank\" rel=\"noreferrer noopener\">immunoter\u00e0pies <\/a>actuals siguin ineficaces per a molts pacients. VIOLET Pharmaceuticals pret\u00e9n superar aix\u00f2 <strong>obligant les c\u00e8l\u00b7lules tumorals a expressar la prote\u00efna LCOR<\/strong>, un regulador clau de la \u00abvisibilitat\u00bb del tumor que promou la presentaci\u00f3 de neoant\u00edgens i permet el reconeixement del sistema immunitari. <strong>Combinant <\/strong>estrat\u00e8gies basades en LCOR <strong>amb la <a href=\"https:\/\/ellipse.prbb.org\/ca\/que-es-la-immunoterapia\/\">immunoter\u00e0pia<\/a><\/strong>, l&#8217;empresa busca obrir <a href=\"https:\/\/ellipse.prbb.org\/ca\/una-nova-diana-per-evitar-la-metastasi-abans-que-es-manifesti\/\" target=\"_blank\" rel=\"noreferrer noopener\">noves possibilitats de tractament, especialment per al c\u00e0ncer de mama metast\u00e0tic<\/a>, que afecta al voltant del 30% de les pacients amb <a href=\"https:\/\/ellipse.prbb.org\/ca\/tag\/cancer-de-mama\/\" target=\"_blank\" rel=\"noreferrer noopener\">c\u00e0ncer de mama<\/a> i continua sent incurable.<\/p>\n\n\n\n<div style=\"height:47px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\"><p>\u00abEn for\u00e7ar les c\u00e8l\u00b7lules tumorals a expressar LCOR, podem fer-les visibles per al sistema immunitari. Combinant LCOR amb immunoter\u00e0pia, obrim la porta al tractament del c\u00e0ncer de mama metast\u00e0tic<em>\u00ab<\/em><br><strong><a href=\"https:\/\/ellipse.prbb.org\/ca\/toni-celia-terrassa-imim-en-ciencia-necessites-molta-sort-pero-per-tenir-la-lhas-de-buscar-amb-constancia-i-perseveranca\/\" target=\"_blank\" rel=\"noreferrer noopener\">Toni Celi\u00e0-Terrassa<\/a> <\/strong>(Hospital del Mar Research Institute i CSO de VIOLET Pharmaceuticals)<\/p><\/blockquote>\n\n\n\n<div style=\"height:47px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p class=\"wp-block-paragraph\">L&#8217;empresa est\u00e0 <strong>desenvolupant una nanoter\u00e0pia basada en ARNm<\/strong>, la primera d&#8217;aquest tipus, inspirada en la tecnologia utilitzada en les vacunes contra la COVID-19, per administrar l&#8217;ARN missatger LCOR directament a les c\u00e8l\u00b7lules tumorals. <strong>Els estudis precl\u00ednics ja han demostrat respostes completes en diversos models experimentals<\/strong> de c\u00e0ncer de mama, generant propietat intel\u00b7lectual en un camp on actualment no existeixen ter\u00e0pies aprovades.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong><a href=\"https:\/\/www.imim.cat\/noticies\/1406\/violet-pharmaceuticals-la-nova-spin-off-de-lhospital-del-mar-research-institute-barcelona-augmenta-leficacia-de-les-immunoterapies-per-als-cancers-metastatics\" target=\"_blank\" rel=\"noreferrer noopener\">VIOLET Pharmaceuticals ha obert una ronda de finan\u00e7ament <\/a><\/strong>per finalitzar l&#8217;optimitzaci\u00f3 del seu candidat cl\u00ednic i ampliar la validaci\u00f3 precl\u00ednica en m\u00faltiples tipus de c\u00e0ncer, amb l&#8217;objectiu d&#8217;associar-se amb una empresa farmac\u00e8utica entre el 2030 i el 2032.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Amb seu al <a rel=\"noreferrer noopener\" href=\"http:\/\/www.prbb.org\" target=\"_blank\">Parc de Recerca Biom\u00e8dica de Barcelona (PRBB)<\/a>, l&#8217;empresa emergent es converteix en la <strong>quarta spin-off recolzada per l&#8217;Hospital del Mar Research Institute<\/strong>, \u200b\u200brefor\u00e7ant el seu paper com a centre l\u00edder en innovaci\u00f3 biom\u00e8dica i transfer\u00e8ncia de tecnologia.<\/p>\n\n\n\n<div style=\"height:58px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>La nova spin-off del Hospital del Mar Research Institute t\u00e9 com a objectiu desenvolupar el primer tractament basat en ter\u00e0pia d&#8217;ARNm per al c\u00e0ncer de mama metast\u00e0tic.<\/p>\n","protected":false},"author":6,"featured_media":50312,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[26],"tags":[312,497,213,413,726],"new-type":[35],"class_list":["post-50318","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-recerca","tag-cancer-ca","tag-cancer-de-mama","tag-imim","tag-immunoterapia","tag-innovacio","new-type-noticies"],"acf":[],"_links":{"self":[{"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/posts\/50318","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/comments?post=50318"}],"version-history":[{"count":4,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/posts\/50318\/revisions"}],"predecessor-version":[{"id":50322,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/posts\/50318\/revisions\/50322"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/media\/50312"}],"wp:attachment":[{"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/media?parent=50318"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/categories?post=50318"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/tags?post=50318"},{"taxonomy":"new-type","embeddable":true,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/new-type?post=50318"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}